Patent · US Active

Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen

US8765787B2 · kind B2 · utility

7Cited by

12References

9Claims

0Family size

Assignee

Bridge Pharma, Inc. · US

Inventors

A.K. Gunnar Aberg · Sarasota, US
Keith Johnson · Durham, US

Key dates

Filing date	Nov 20, 2009
Grant date	Jul 1, 2014
Priority date	—
Expiry date	Jan 1, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P27/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Self-preserving ophthalmic formulations containing norketotifen and methods of making the same and the use thereof in patients suffering from xerophthalmia are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof, self-preserving topical ophthalmic formulations containing norketotifen, free from any added preservative.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.